These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 35165712)
21. Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease: Authors' reply. Tfelt-Hansen J; Svendsen JH; Kalarus Z; Capodanno D; Dan GA; De Maria E; Gorenek B; Jedrzejczyk-Patej E; Mazurek M; Podolecki T; Sticherling C; Traykov V; Lip GYH Europace; 2020 Oct; 22(10):1600-1601. PubMed ID: 32236547 [No Abstract] [Full Text] [Related]
22. Patient selection for wearable cardioverter defibrillator therapy after myocardial infarction: How can we incorporate compliance into decision-making? Younis A; Goldenberg I J Cardiovasc Electrophysiol; 2020 May; 31(5):1019-1021. PubMed ID: 32083370 [No Abstract] [Full Text] [Related]
23. Usefulness of the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Sasaki S; Tomita H; Shibutani S; Izumiyama K; Higuma T; Itoh T; Sasaki K; Horiuchi D; Kimura M; Okumura K Circ J; 2014; 78(12):2987-9. PubMed ID: 25366562 [TBL] [Abstract][Full Text] [Related]
24. [Implantable cardioverter defibrillators in the prevention of sudden cardiac death]. Bockeria LA; Neminushchiy NM; Mikhaylichenko SI; Novichkov SA; Achkasov EE Ter Arkh; 2017; 89(12):103-109. PubMed ID: 29411768 [TBL] [Abstract][Full Text] [Related]
25. Oversensing of the wearable cardioverter defibrillator during bipolar ventricular stimulation. Manninger M; Odeneg T; Fruhwald F; Brussee H; Scherr D Wien Klin Wochenschr; 2017 Dec; 129(23-24):910-912. PubMed ID: 29124430 [TBL] [Abstract][Full Text] [Related]
26. [The unmet needs of sudden cardiac death. The role of the wearable cardioverter defibrillator when the risk is transient or uncertain]. Guerra F; Palmisano P; Bisignani G; Forleo G; Landolina M; Soldati E; Stabile G; Zanotto G; Berisso MZ; Boriani G; De Ponti R; Ricci RP G Ital Cardiol (Rome); 2020 Oct; 21(10):764-767. PubMed ID: 32968313 [TBL] [Abstract][Full Text] [Related]
27. An optimized long QT syndrome differentiating protocol: A new indication for wearable cardioverter-defibrillator vests. Pilawa M; Kaźmierczak J; Kiedrowicz RM Kardiol Pol; 2022; 80(7-8):857-858. PubMed ID: 35677993 [No Abstract] [Full Text] [Related]
28. Wearable cardioverter-defibrillators: A review of evidence and indications. Cheung CC; Olgin JE; Lee BK Trends Cardiovasc Med; 2021 Apr; 31(3):196-201. PubMed ID: 32205034 [TBL] [Abstract][Full Text] [Related]
29. The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital. Sinha AM; Bense J; Hohenforst-Schmidt W J Interv Card Electrophysiol; 2021 Nov; 62(2):401-407. PubMed ID: 33200285 [TBL] [Abstract][Full Text] [Related]
30. The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients. Spar DS; Bianco NR; Knilans TK; Czosek RJ; Anderson JB Circ Arrhythm Electrophysiol; 2018 Jul; 11(7):e006163. PubMed ID: 29945928 [TBL] [Abstract][Full Text] [Related]
32. Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study. Garcia R; Combes N; Defaye P; Narayanan K; Guedon-Moreau L; Boveda S; Blangy H; Bouet J; Briand F; Chevalier P; Cottin Y; Da Costa A; Degand B; Deharo JC; Eschalier R; Extramiana F; Goralski M; Guy-Moyat B; Guyomar Y; Hermida JS; Jourda F; Lellouche N; Mahfoud M; Manenti V; Mansourati J; Martin A; Pasquié JL; Ritter P; Rollin A; Tibi T; Yalioua A; Gras D; Sadoul N; Piot O; Leclercq C; Marijon E Europace; 2021 Jan; 23(1):73-81. PubMed ID: 33257972 [TBL] [Abstract][Full Text] [Related]
33. Cost-minimization analysis of a wearable cardioverter defibrillator in adult patients undergoing ICD explant procedures: Clinical and economic implications. Boriani G; Mantovani LG; Cortesi PA; De Ponti R; D'Onofrio A; Arena G; Curnis A; Forleo G; Guerra F; Porcu M; Sgarito G; Botto GL Clin Cardiol; 2021 Nov; 44(11):1497-1505. PubMed ID: 34427926 [TBL] [Abstract][Full Text] [Related]
34. Device Therapy for Sudden Cardiac Death Prophylaxis After Acute Coronary Syndrome: When and Why? Beg F; Valderrabano M; Schurmann P Curr Cardiol Rep; 2020 Jan; 22(1):4. PubMed ID: 31950276 [TBL] [Abstract][Full Text] [Related]
36. Successful Management of a Young Athlete with Type 2 Long QT Syndrome by Genotype-specific Risk Stratification and Bridging Therapy with a Wearable Cardioverter Defibrillator. Kojima K; Kato K; Fujii Y; Okuyama Y; Ohno S; Ozawa T; Horie M; Nakagawa Y Intern Med; 2022 Apr; 61(8):1179-1182. PubMed ID: 35110475 [TBL] [Abstract][Full Text] [Related]
37. Mitigating Post-Extraction Risk: Is it Worth the inVESTment? Chung MK JACC Clin Electrophysiol; 2017 Mar; 3(3):251-252. PubMed ID: 29759519 [No Abstract] [Full Text] [Related]
38. [ANMCO Position paper: Wearable cardioverter defibrillator appropriate use guidance for the management of patients at high transient risk of sudden cardiac death]. Casolo G; Gulizia MM; Aschieri D; Chinaglia A; Corda M; Nassiacos D; Caico SI; Chimenti C; Giaccardi M; Gotti E; Maffè S; Magnano R; Solarino G; Gabrielli D; Oliva F; Colivicchi F G Ital Cardiol (Rome); 2023 May; 24(5):394-411. PubMed ID: 37102354 [TBL] [Abstract][Full Text] [Related]
39. Telemedical Concepts for Heart Failure Patients Treated with a Wearable Cardioverter Defibrillator. Reiss N; Schmidt T; Hoffmann JD; Kunzendorf S; Luegmair G; Tröger T; Buj C; Müller-von Aschwege F Stud Health Technol Inform; 2020 Jun; 271():93-100. PubMed ID: 32578547 [TBL] [Abstract][Full Text] [Related]
40. The applications of Wearable Cardioverter Defibrillators in Heart Failure and beyond. Rocco E; Angelini A; Simeone B; Grimaldi MC; Pinnacchio G; Narducci ML; Pelargonio G Clin Ter; 2023; 174(1):85-92. PubMed ID: 36655650 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]